Liam Masterson

Dr. Liam Masterson

Cambridge University NHS Foundation Trust
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
LMLiam Masterson
Liam Masterson
DMDaniel Moualed
Daniel Moualed
ZLZi Wei Liu
Zi Wei Liu
JHJames E.F. Howard
James E.F. Howard
RDRaghav C. Dwivedi
Raghav C. Dwivedi
PGPeter K.C. Goon
Peter K.C. Goon

2 December 2014 in The Laryngoscope
Verified
Journal Article
Closed access
MKMong‐Loon Kuet
Mong‐Loon Kuet
AKAnand V. Kasbekar
Anand V. Kasbekar
LMLiam Masterson
Liam Masterson
PJPiyush Jani
Piyush Jani

13 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DBDaniele Borsetto
Daniele Borsetto
MTMichele Tomasoni
Michele Tomasoni
KPKarl Payne
Karl Payne
Jerry PoleselJerry Polesel
Jerry Polesel
ADAlberto Deganello
Alberto Deganello
PBPaolo Boscolo-Rizzo
Paolo Boscolo-Rizzo
Objective: It has been suggested that the presence of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment is associated with a better prognosis in different types of cancer. In this systematic review and meta-analysis, we investigated the prognostic role of CD4+ and CD8+ TILs in head and neck squamous cell carcinoma (HNSCC). Methods: PubMed, Cochrane, Embase, Scopus, and Web of Science were searched up to September 2020. This study was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. Risk ratios from individual studies were displayed in forest plots and the pooled hazard ratios (HR) of death and corresponding confidence intervals (CI) were calculated according to random-effects models. Risk of bias of the included studies was assessed through the Newcastle–Ottawa scale. Results: 28 studies met the inclusion criteria. Studies conducted on HNSCC subsites combined reported a significant reduction in the risk of death for both high CD4+ (HR: 0.77; 95% CI: 0.65–0.93) and high CD8+ TILs (HR: 0.64; 95% CI: 0.47–0.88). High CD4+ TILs were associated with significantly better overall survival among oropharyngeal HNSCC (HR: 0.52; 95% CI: 0.31–0.89), as well as high CD8+ TILS in Human papillomavirus −ve and +ve cancers (HR: 0.39; 95% CI: 0.16–0.93 and HR: 0.40; 95% CI 0.21–0.76 respectively). CD8+ TILs were also associated with improved survival in hypopharyngeal cancers (HR = 0.43 CI: 0.30–0.63). No significant association emerged for patients with cancer of the oral cavity or larynx. Conclusions: The findings from this meta-analysis demonstrate the prognostic significance of CD8+ and CD4+ TILs in HNSCC and variation in tumor subsite warrants further focused investigation. We highlight how TILs may serve as predictive biomarkers to risk stratify patients into treatment groups, with applications in immune-checkpoint inhibitors notable areas for further research.

18 March 2010 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
LMLiam Masterson
Liam Masterson
FTFaiz Tanweer
Faiz Tanweer
TBTeofila Bueser
Teofila Bueser
PLPaul Leong
Paul Leong

1 November 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
LMLiam Masterson
Liam Masterson
MLMatt Lechner
Matt Lechner
SLSarah Loewenbein
Sarah Loewenbein
HMHassan Mohammed
Hassan Mohammed
CDCameron Davies-Husband
Cameron Davies-Husband
JSJane Sterling
Jane Sterling

1 August 2018 in Oral Oncology
Verified
Journal Article
Closed access
MLMatt Lechner
Matt Lechner
ACAnkur R. Chakravarthy
Ankur R. Chakravarthy
VWVonn Walter
Vonn Walter
LMLiam Masterson
Liam Masterson
AFAndrew Feber
Andrew Feber
TFTim Fenton
Tim Fenton